Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Mouse Monoclonal [clone ON1-1] (IgG1) to Bovine Osteonectin / SPARC
IHC - Paraffin, IHC - Frozen, Western blot
Bovine Osteonectin / SPARC
Bovine, Human (tested or 100% immunogen sequence identity)
IgG1 Monoclonal [ON1-1]
IHC - Paraffin (1 - 10 µg/ml)
IHC - Frozen (1 - 10 µg/ml)
Western blot (1 - 10 µg/ml)
Specificity and Use
Bovine bone osteonectin.
Reacts with human and bovine osteonectin as determined by Western Blot, and cross-reacts with rabbit and porcine osteonectin as determined by ELISA. Reacts with both bone and platelet derived osteonectin; it does not react with non-activated platelets, but it does react with thrombin-stimulated platelets, as determined by Flow Cytometry.
Western Blot: Reducing and non-reducing conditions.
Lyophilized from 10 mM PBS, pH 7.4 with 1% BSA
50 µl Distilled Water.
Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles.
SPARC Antibody, Basement-membrane protein 40 Antibody, BM-40 Antibody, Cysteine-rich protein Antibody, ON Antibody, Osteonectin Antibody
SPARC (secreted protein acidic and rich in cysteine)/Osteonectin is a matricellular glycoprotein that modulates cellular interactions with the ECM and is expressed in tissues undergoing remodeling. It functions as a de-adhesive protein, as a modulator of growth factor activity, and as a cell-cycle inhibitor. It induces changes in endothelial cell shape via F-actin, coincident with the appearance of intercellular gaps, that provide a paracellular pathway for extravasation of macromolecules.